Best deal of the week



Instruction for use: Aspirin Cardio

I want this, give me price

Dosage form: enteric-coated tablet

Active substance: Acidum acetylsalicylicum


B01AC06 Acetylsalicylic acid

Pharmacological groups

Non-steroidal anti-inflammatory drug (NSAID) [Antiaggregants]

Non-steroidal anti-inflammatory drug (NSAID) [NSAIDs - Salicylic acid derivatives]

Nosological classification (ICD-10)

E14 Diabetes mellitus, unspecified: Severe vascular complication of diabetes: Diabetes; Diabetic asthenia; Thyroid dysfunction; Diabetes; Obesity in the background of diabetes

G45 Transient transient cerebral ischemic attacks [attacks] and related syndromes: Ischemic neurological disorders; Acute cerebrovascular insufficiency; Repeated transient cerebral ischemia; Transient ischemic attack; Transient ischemic condition; Transient ischemic attack; Transient ischemic attack; transient ischemia; Transient cerebral ischemic attack; Transient cerebral ischemia; Transient ischemic attacks; Chronic cerebral ischemia; Drop attacks; Transient ischemic attacks; Transient ischemic cerebrovascular accident; Ischemic brain damage; Subclavian steal syndrome

I10 Essential (primary) hypertension: hypertension; Arterial hypertension; Arterial hypertension crisis course; Essential Hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Primary hypertension; Arterial hypertension, complications of diabetes; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; arterial Hypertension; malignant Hypertension; Hypertonic disease; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; Isolated systolic hypertension

I15 Secondary hypertension: Arterial hypertension, complications of diabetes; hypertension; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; hypertension; arterial Hypertension; malignant Hypertension; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; hypertension; Arterial hypertension; Arterial hypertension crisis course; renovascular hypertension; Hypertension symptomatic; Renal hypertension; Renovascular hypertension; renovascular hypertension; Symptomatic hypertension

I20 Angina [angina]: Heberden disease; Angina pectoris; The attack of angina pectoris; recurrent angina; Spontaneous angina; Stable angina pectoris; Angina rest; Angina progressing; Angina mixed; Angina spontaneous; stable angina; Chronic stable angina; Angina Syndrome X

I20.0 Unstable angina: heberden disease; Angina pectoris; The attack of angina pectoris; recurrent angina; Spontaneous angina; Stable angina pectoris; Angina rest; Angina progressing; Angina mixed; Angina spontaneous; stable angina; Chronic stable angina; Angina Syndrome X

I21 Acute myocardial infarction: Myocardial infarction in the acute phase; Acute Myocardial Infarction; Myocardial infarction with pathologic Q wave and without; Myocardial infarction complicated by cardiogenic shock; Infarction left ventricular; Transmural myocardial infarction; Myocardial infarction netransmuralny (subendocardial); Netransmuralny myocardial infarction; Subendocardial myocardial infarction; The acute phase of myocardial infarction; Acute myocardial infarction;Sub-acute phase of myocardial infarction; Subacute phase of myocardial infarction; Thrombosis of the coronary arteries (the arteries); Threatened myocardial infarction; Myocardial infarction without Q wave

I22 Subsequent myocardial infarction: Atherosclerosis and the likelihood of reinfarction; Myocardial infarction re; Relapses myocardial infarction

I26.9 Pulmonary embolism without mention of acute pulmonary heart: pulmonary infarction

I63 Cerebral infarction: ischemic Stroke; Ischemic brain disease; Ischemic stroke; Ischemic stroke and its consequences; Ischemic cerebral stroke; Ischemic cerebrovascular accident; Ischemic brain damage; Ischemic brain damage; ischemic conditions; Cerebral ischemia; Acute hypoxia brain; Acute cerebral ischemia; Acute ischemic cerebrovascular accident; Acute cerebral infarction; Acute ischemic stroke; Acute period of ischemic stroke; Focal cerebral ischemia; Ischemic stroke; recurrent stroke; The syndrome of Morgagni-Adams-Stokes; Chronic cerebral ischemia; cerebrovascular stroke; embolic stroke; Ischemic brain damage

I64 Unspecified Stroke as a bleeding or heart attack: Primary stroke; Stroke; Stroke in the course of; microstroke; stroke; The completed stroke

I74 Embolism and arterial thrombosis: Thrombosis of effort (stress); Arterial thrombosis; Arteriothrombosis; Subacute and chronic arterial thrombosis; Subacute thrombosis of peripheral arteries; Postoperative thrombosis; Vascular thrombosis; Vascular embolism; Thrombosis of aortocoronary shunt; Arterial thrombosis; Thrombosis of arteries; Coronary artery thrombosis; Coronary thrombosis; Thrombosis of blood vessels; Thrombosis with ischemic stroke; Thrombosis with general surgical operations; Thrombosis in Oncology Operations; Vascular thrombosis; Thrombus formation in the postoperative period; Thrombotic complications; Thromboembolic diseases; Thromboembolic syndrome; Thromboembolic complication in the postoperative period; Thromboembolism of arteries; Partial vascular thrombosis; Embolism; Embolism of arteries

I82.8 Embolism and thrombosis of other specified veins: Acute deep vein thrombosis; Acute thrombosis of the deep veins of the extremities and pelvis; Acute thrombosis of deep veins of legs; Venous thrombosis of the vessels of the eye; Thrombosis of veins of internal organs; Deep vein thrombosis of the lower extremities; Thrombosis of subclavian veins

R54 Age-related disease: External signs of aging; Age-related eye disease; Age-related visual impairment; Age-related vascular disease; Age constipation; Age-related changes in visual acuity; Age-related changes in the brain involutional; Age-related disorders; Age-related hearing loss; gerontological practice; senile dementia; Deficiency of calcium and vitamin D3 in the elderly; cerebral vascular disease and age-related; involutionary depression; involutional depression; Correction of metabolism in middle and old age; Malnutrition in elderly and senile age.; senile dementia; senile dementia; senile depression; senile colpites; senile psychosis; Syndrome of age involution; Hearing loss age; Aging; Brain Aging; The aging of the organism; senile dementia; senium; Senile involutional psychosis; senile psychosis; Memory impairment in elderly patients; Conduct disorders in the elderly

Z100 * CLASS XXII Surgical practice: Abdominal surgery; adenomectomy; Amputation; Coronary angioplasty; Angioplasty of the carotid arteries; Antiseptic skin treatment for wounds; Antiseptic Hand; Appendectomy; atherectomy; Balloon coronary angioplasty; Vaginal hysterectomy; The coronary bypass; Interventions in the vagina and cervix; Interventions on the bladder; Intervention in the mouth; Restoration and reconstructive surgery; Hand hygiene of medical personnel; Gynecologic surgery; Gynecological intervention; Gynecological surgery; Hypovolemic shock during operations; Disinfection of purulent wounds; Disinfection of wounds edges; Diagnostic intervention; Diagnostic procedures; Cervical Diathermocoagulation; Long-surgery; Replacing the fistula catheters; Infection in orthopedic surgery; Artificial heart valve; cystectomy; Short-term outpatient surgery; Short-term operation; Short surgical procedures; Krikotireotomiya; Blood loss during surgery; Bleeding during surgery and in the postoperative period; Kuldotsentez; laser photocoagulation; laser coagulation; retinal laser coagulation; Laparoscopy; Laparoscopy in Gynecology; CSF fistula; Small gynecological operations; Small surgical procedures; Mastectomy and subsequent plastic; mediastinotomy; Microsurgical operations on the ear; Mukogingivalnye operation; suturing; Minor surgery; neurosurgical operation; Immobilization of the eyeball in ophthalmic surgery; testectomy; pancreatectomy; Perikardektomiya; The period of rehabilitation after surgery; The period of convalescence after surgery; Percutaneous transluminal coronary angioplasty; Pleural thoracentesis; Pneumonia postoperative and posttraumatic; Preparation for surgical procedures; Preparation for surgery; Preparation of the surgeon's hands before surgery; Preparation of the colon for surgical procedures; Postoperative aspiration pneumonia in neurosurgical and thoracic surgery; Postoperative nausea; Postoperative bleeding; postoperative granuloma; postoperative shock; The early postoperative period; myocardial revascularization; Radiectomy; gastric Resection; bowel resection; uterine Resection; liver Resection; enterectomy; Resection of part of the stomach; Reocclusion of the operated vessel; Bonding tissues during surgical procedures; Removal of sutures; Condition after eye surgery; Condition after surgery; Condition after surgery in the nasal cavity; Condition after gastrectomy; Status after resection of the small intestine; Condition after tonsillectomy; Condition after removal of the duodenum; Condition after phlebectomy; Vascular surgery; Splenectomy; Sterilization of surgical instruments; Sterilization of surgical instruments; sternotomy; Dental surgery; Dental intervention in periodontal tissues; strumectomy; Tonsillectomy; Thoracic surgery; Thoracic surgery; total gastrectomy; Transdermal intravascular coronary angioplasty; Transurethral resection; Turbinektomiya; Removal of a tooth; cataract surgery; Removal of cysts; tonsillectomy; Removal of fibroids; Removing the mobile primary teeth; Removing polyps; Removing broken tooth; Removal of the uterus body; Removal of sutures; Fistula likvoroprovodyaschih ways; Frontoetmoidogaymorotomiya; Surgical infection; Surgical treatment of chronic limb ulcers; Surgery; The surgery in the anal area; The surgery on the colon; Surgical practice; The surgical procedure; Surgical interventions; Surgery on the gastrointestinal tract; Surgical procedures on the urinary tract; Surgical procedures on the urinary system; Surgical intervention of the genitourinary system; Surgical procedures on the heart; Surgical manipulation; surgery; Surgery on the veins; Surgical intervention; Vascular surgery; Surgical treatment of thrombosis; Surgery; cholecystectomy; Partial gastric resection; hysterectomy; Percutaneous transluminal coronary angioplasty; Percutaneous transluminal angioplasty; Coronary artery bypass; tooth Extirpation; Extirpation of milk teeth; pulpectomy; pulsative cardiopulmonary bypass; tooth Extraction; teeth Extraction; cataract extraction; Electrocoagulation; endourological intervention; episiotomy; Etmoidotomiya; Complications after tooth extraction

Z72.0 Tobacco use: tobacco smoking, Smoking

Z95.1 Presence of aortocoronary shunt transplant: Coronary artery bypass grafting; Aortocoronary bypass with venous shunt

Z95.5 Presence of coronary angioplasty implant and graft: Coronary artery bypass grafting; Arteriovenous shunting; Thrombosis of arteriovenous shunt

Structure and Composition

active substance: Acetylsalicylic acid - 100 mg, 300 mg

Auxiliary substances: cellulose powder - 10 or 30 mg; Corn starch - 10 or 30 mg

Composition of the shell: a copolymer of methacrylic acid and ethacrylate 1: 1 (Eudragit L30D) - 7.857 or 27, 709 mg; Polysorbate 80 - 0.186 or 0.514 mg; Sodium lauryl sulfate - 0.057 or 0.157 mg; Talc - 8.1 or 22.38 mg; Triethyl citrate 0.8 or 2.24 mg

Description of dosage form

Round, biconvex tablets are white, in cross section - a homogeneous mass of white, with a shell of the same color.

Pharmachologic effect

Mode of action - antiaggregatory.


The mechanism of antiaggregatory action of ASA is based on the irreversible inhibition of COX-1, which blocks the synthesis of thromboxane A2 and suppresses platelet aggregation. The antiaggregation effect is most pronounced in platelets, because They are not able to re-synthesize COX. It is believed that ASA has other mechanisms for suppressing platelet aggregation, which expands its use in various vascular diseases.

ASA also has anti-inflammatory, analgesic and antipyretic effects.


After ingestion, acetylsalicylic acid (ASA) is rapidly and completely absorbed from the digestive tract. ASA is partially metabolized during absorption. During and after absorption, ASA converts to a major metabolite, salicylic acid, which is metabolized mainly in the liver under the influence of enzymes to form metabolites such as phenyl salicylate, glucuronide salicylate, and salicyluric acid found in many tissues and in urine. In women, the metabolic process is slower (less enzyme activity in the blood serum). Cmax ASA in blood plasma is achieved 10-20 minutes after ingestion, salicylic acid - after 0.3-2 hours. Due to the fact that the tablets are covered with an acid-resistant coating, ASA is not released in the stomach (the membrane effectively blocks dissolution of the drug in the stomach), But in the alkaline medium of the duodenum. Thus, the absorption of ASA in the form of enteric coated tablets is delayed by 3 to 6 hours compared to conventional tablets (without such a coating).

ASA and salicylic acid strongly bind to blood plasma proteins (from 66 to 98% depending on the dose) and are quickly distributed in the body. Salicylic acid penetrates the placenta and is excreted in breast milk.

Elimination of salicylic acid is dose-dependent, since its metabolism is limited by the capabilities of the enzymatic system. T1 / 2 is 2-3 hours when using ASA in low doses and up to 15 hours when the drug is used in high doses (the usual dose of ASA as an analgesic agent). Unlike other salicylates, with repeated administration of the drug, unhydrolyzed ASA does not accumulate in the blood serum. Salicylic acid and its metabolites are excreted by the kidneys. In patients with normal renal function 80-100% of a single dose of the drug is excreted by the kidneys within 24-72 hours.

Indications for the drug Aspirin Cardio

Primary prevention of acute myocardial infarction in the presence of risk factors (eg diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) and repeated myocardial infarction;

Unstable angina (including suspected development of acute myocardial infarction) and stable angina pectoris;

Prevention of stroke (including in patients with transient impairment of cerebral circulation);

Prophylaxis of transient cerebral circulation;

Prevention of thromboembolism after surgery and invasive vascular interventions (eg coronary artery bypass grafting, carotid endarterectomy, arteriovenous shunting, angioplasty and stenting of the coronary arteries, carotid angioplasty);

Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (including with prolonged immobilization as a result of extensive surgical intervention).


Increased sensitivity to ASA, drug auxiliaries and other NSAIDs;

Bronchial asthma induced by the intake of salicylates and NSAIDs, aspirin triad (a combination of bronchial asthma, recurrent nasal polyposis and paranasal sinuses and ASA intolerance);

Erosive and ulcerative lesions of the gastrointestinal tract (in the stage of exacerbation), gastrointestinal bleeding;

Hemorrhagic diathesis;

Combined use with methotrexate at a dose of 15 mg per week or more;

Pregnancy (I and III trimester);

The period of breastfeeding;

Children and adolescence (up to 18 years);

Severe renal insufficiency (Cl creatinine <30 ml / min);

Severe hepatic insufficiency (class B and higher on the Child-Pugh scale);

Chronic heart failure of III-IV functional class according to NYHA classification.


With the following diseases and conditions:

gout; Hyperuricemia (because ASA reduces uric acid excretion in low doses, it should be borne in mind that ASA in low doses can provoke the development of gout in predisposed patients who have decreased urinary acid excretion);

Presence in the anamnesis of ulcerative lesions of the gastrointestinal tract or gastrointestinal bleeding;

Impaired liver function (below grade B on the Child-Pugh scale);

Impaired renal function (Cl creatinine> 30 ml / min), as well as circulatory disorders resulting from arteriosclerosis of the renal arteries, congestive heart failure, hypovolemia, extensive surgical intervention, sepsis, cases of massive bleeding, as in all listed cases, ASA may increase the risk of developing Acute renal failure and impaired renal function;

Bronchial asthma, chronic respiratory diseases, hay fever, nasal polyposis, drug allergy, incl. On preparations of the group of NSAIDs (analgesics, anti-inflammatory, antirheumatic drugs);

II trimester of pregnancy;

Anticipated surgical intervention (including minor, for example tooth extraction), because ASA may cause a tendency to develop bleeding within a few days after taking the drug;

Combined use with the following drugs (see section "Interaction"): methotrexate in a dose of less than 15 mg per week; Anticoagulant, thrombolytic or antiplatelet agents; NSAIDs and derivatives of salicylic acid in large doses; Digoxin; Hypoglycemic agents for oral administration (sulfonyl-urea derivatives) and insulin; Valproic acid; Alcohol (alcoholic beverages in particular); Selective serotonin reuptake inhibitors; Ibuprofen.

Pregnancy and breast-feeding

Inhibition of GHG synthesis may have a negative effect on pregnancy and the development of an embryo or fetus.

In the first trimester of pregnancy, the use of large doses of salicylates (more than 300 mg / day, the dosage of ASA from 500 mg - as an anesthetic) is associated with an increased incidence of fetal development defects (cleft palate, heart defects). The appointment of salicylates in the first trimester of pregnancy is contraindicated.

In the second trimester of pregnancy, salicylates can only be given in view of strict risk and benefit evaluation for the mother and fetus, preferably at doses not exceeding 150 mg / day and for a short time.

In the third trimester of pregnancy, salicylates in high doses (more than 300 mg / day, the dosage of ASA from 500 mg - as an anesthetic) can cause inhibition of labor, premature closure of the arterial duct in the fetus, increased bleeding in the mother and fetus, and The appointment immediately before childbirth can cause intracranial hemorrhages, especially in premature infants. The appointment of salicylates in the third trimester of pregnancy is contraindicated.

Application in the period of lactation. Salicylates and their metabolites penetrate into breast milk in small amounts. The accidental intake of salicylates during lactation is not accompanied by the development of adverse reactions in the child and does not require the cessation of breastfeeding. However, with prolonged use of the drug or its administration in a high dose, breast-feeding should be stopped immediately.

Side effects

From the side of the digestive system: most often there are nausea, heartburn, vomiting, abdominal pain; Rarely ulcers of the mucous membrane of the stomach and duodenum; Very rarely - perforated ulcers of the mucous membrane of the stomach and duodenum, gastrointestinal bleeding (with the corresponding clinical symptoms and laboratory changes), transient liver dysfunction with increased activity of hepatic transaminases.

On the part of the hematopoietic system: the administration of ASA is accompanied by an increased risk of bleeding due to its inhibitory effect on platelet aggregation. An increase in the frequency of perioperative (intra- and post-operative) bleeding, hematomas (bruises), nasal bleeding, gum bleeding, bleeding from the urogenital tract has been reported. There are reports of serious bleeding events, including gastrointestinal bleeding and cerebral hemorrhage (especially in patients with hypertension who have not reached the target BP figures and / or are receiving concomitant therapy with anticoagulant drugs), which in some cases may be life-threatening (See section "Special instructions").

Bleeding can lead to the development of acute or chronic posthemorrhagic / iron deficiency anemia (eg due to latent bleeding) with appropriate clinical and laboratory signs and symptoms (asthenia, pallor, hypoperfusion).

There are reports of hemolysis and hemolytic anemia in patients with severe forms of glucose-6-phosphate dehydrogenase deficiency.

Allergic reactions: hypersensitivity reactions are possible with appropriate laboratory and clinical manifestations, such as asthmatic syndrome (bronchospasm), mild to moderate skin reactions, respiratory tract, gastrointestinal tract and SSS, including symptoms such as skin rash, itching, Urticaria, Quincke's edema, edema of the nasal mucosa, rhinitis, cardiorespiratory distress syndrome, and severe reactions, including anaphylactic shock.

From the side of the central nervous system: there are reports of cases of dizziness, hearing loss, headache, tinnitus, which may be a sign of drug overdose (see section "Overdose").

From the side of the urinary system: there are reports of cases of development of renal dysfunction and acute renal failure.


With the simultaneous use of ASA enhances the effect of the following drugs; If it is necessary to simultaneously prescribe ASA with the listed drugs, consider the need to reduce the dose of these drugs:

- Methotrexate - by reducing renal clearance and displacing it from the bond with proteins; The combination of ASA with methotrexate is accompanied by an increased incidence of side effects on the part of the hematopoiesis; Use of AspirinŽ Cardio together with methotrexate is contraindicated if the dose of the latter exceeds 15 mg per week (see the section "Contraindications"); And possibly with caution - with a dose of methotrexate less than 15 mg per week;

- heparin and indirect anticoagulants - due to disruption of platelet function and displacement of indirect anticoagulants from binding to proteins; When used simultaneously with anticoagulants, thrombolytic and antiplatelet agents (ticlopidine), there is an increased risk of bleeding as a result of synergism of the main therapeutic effects of the drugs used and an increase in the damaging effect on the gastrointestinal mucosa;

Selective serotonin reuptake inhibitors; Possibly increased risk of bleeding from the upper GI tract (synergy with ASA);

- Digoxin - due to a decrease in its renal excretion, which can lead to its overdose;

- hypoglycemic agents for oral administration (derivatives of sulfonylureas) and insulin - due to hypoglycemic properties of ASA itself in high doses and displacement of sulfonylurea derivatives from binding to plasma proteins; This should be borne in mind when assigning ASA to patients with diabetes mellitus receiving the listed drugs;

- concomitant use with valproic acid increases its toxicity due to the displacement of plasma from the connection with proteins;

- NSAID, incl. Derivatives of salicylic acid in high doses (increased risk of ulcerogenic effect and bleeding from the gastrointestinal tract as a result of synergism of action);

- ethanol (alcoholic beverages) - increased risk of damage to the gastrointestinal mucosa and prolongation of bleeding time as a result of mutual enhancement of the effects of ASA and ethanol.

Simultaneous administration of ASA in high doses may impair the effect of the drugs listed below. If it is necessary to simultaneously prescribe ASA with the listed preparations, consideration should be given to the need to correct the dose of the following agents:

- any diuretics (when combined with ASA in high doses, there is a decrease in glomerular filtration rate as a result of decreased synthesis of PG in the kidneys);

- ACE inhibitors - a dose-dependent decrease in the glomerular filtration rate (GFR) is observed as a result of inhibition of PG with vasodilating action, and, accordingly, weakening of the hypotensive effect. The clinical significance of reducing GFR is noted with a daily dose of ASC greater than 160 mg. In addition, there has been a decline in the positive cardioprotective effect of ACE inhibitors assigned to patients for chronic heart failure. This effect is also manifested when applied in conjunction with ASA in large doses;

- drugs with uricosuric action - benzbromarone, probenecid - a decrease in uricosuric effect due to competitive suppression of renal tubular excretion of uric acid.

With simultaneous use with ibuprofen, antagonism is noted with respect to irreversible platelet suppression caused by the action of ASA, which leads to a decrease in the cardioprotective effects of ASA. Therefore, the combination of ASA with ibuprofen in patients with an increased risk of cardiovascular disease is not recommended.

When used simultaneously with systemic SCS (with the exception of hydrocortisone or another SCS used for the replacement therapy of Addison's disease), there is an increased elimination of salicylates and, correspondingly, a weakening of their action. When combined use of GCS and salicylates should be remembered that the level of salicylates in the blood is reduced, and after the abolition of SCS, an overdose of salicylates is possible.

Dosing and Administration

Inside, before eating, squeezed a lot of liquid. AspirinŽ Cardio is intended for long-term use. Tablets should be taken 1 time per day. The duration of therapy is determined by the attending physician.

Primary prevention of acute myocardial infarction in the presence of risk factors - 100 mg / day or 300 mg every other day.

Prevention of recurrent myocardial infarction, stable and unstable angina is 100-300 mg / day.

Unstable angina (with suspected development of acute myocardial infarction) - the initial dose of 100-300 mg (the first tablet must be chewed for faster absorption) should be accepted by the patient as soon as possible after the suspicion of the development of acute myocardial infarction has arisen. In the next 30 days after the development of myocardial infarction, a dose of 200-300 mg / day should be maintained. After 30 days, appropriate therapy should be prescribed to prevent repeated myocardial infarction.

Preventive maintenance of a stroke and a transient infringement of a cerebral circulation - 100-300 mg / sut.

Preventive maintenance of thromboembolism after operations and invasive interventions on vessels - 100-300 mg / day.

Prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches - 100-200 mg / day or 300 mg every other day.

Actions when missing one or more doses of the drug

It is necessary to take the missed tablet as soon as the patient remembers it. To avoid doubling the dose, do not take the missed tablet if the next one is approaching.

Features of the drug at the first admission and when it is canceled. The features of the drug during the first admission and when it was withdrawn was not observed.


Salicylate intoxication (developing with ASA at a dose of more than 100 mg / kg / day for more than 2 days) may result from prolonged use of toxic doses of the drug in the context of improper therapeutic use (chronic intoxication) or a single accidental or intentional intake of a toxic dose of the drug to an adult Or a child (acute intoxication).

Symptoms of chronic intoxication with salicylic acid derivatives are nonspecific and are often diagnosed with difficulty. Intoxication of mild severity usually develops only after repeated use of large doses of the drug and is manifested by dizziness, noise in the ears, hearing loss, increased sweating, nausea and vomiting, headache and confusion. This symptomatology disappears after a decrease in the dose of the drug. Noise in the ears may appear with an ASA concentration in the blood plasma from 150 to 300 μg / ml. More severe symptoms are manifested when the concentration of ASA in the blood plasma is above 300 μg / ml.

The main manifestation of acute intoxication is a severe violation of the acid-base state, the manifestations of which can vary depending on the age of the patient and the severity of intoxication. In children, the development of metabolic acidosis is most typical. Treatment of intoxication is carried out in accordance with accepted standards and depends on the severity of intoxication and clinical picture and should be directed mainly to accelerate the elimination of the drug and restore the water-electrolyte balance and acid-base state.

Symptoms of an overdose from mild to moderate severity: dizziness, tinnitus, hearing impairment, increased sweating, nausea, vomiting, headache, confusion, profuse sweating, tachypnea, hyperventilation, respiratory alkalosis.

Treatment: gastric lavage, repeated intake of activated carbon, forced alkaline diuresis, restoration of water-electrolyte balance and acid-base state.

Symptoms of an overdose from medium to severe: respiratory alkalosis with compensatory metabolic acidosis; Hyperpyrexia (extremely high body temperature); Breathing disorders (hyperventilation, noncardiogenic pulmonary edema, respiratory depression, asphyxia); Violation of the cardiovascular system (cardiac rhythm disturbance, arterial hypotension, oppression of cardiac activity); Disturbance of water-electrolyte balance: dehydration, disturbance of kidney function from oliguria up to the development of renal insufficiency, characterized by hypokalemia, hypernatremia, hyponatremia; Impaired glucose metabolism (hyperglycemia, hypoglycemia (especially in children), ketoacidosis); Noise in the ears, deafness; Gastrointestinal bleeding; Hematologic disorders (from inhibition of platelet aggregation to coagulopathy, lengthening of PV, hypoprothrombinemia); Neurological disorders (toxic encephalopathy and depression of CNS function (drowsiness, confusion, coma, convulsions).

Treatment: immediate hospitalization in specialized departments for emergency therapy - gastric lavage, repeated intake of activated carbon, forced alkaline diuresis, hemodialysis, restoration of water-electrolyte balance and acid-base state, symptomatic therapy.

Special instructions

The drug should be used as directed by a doctor.

ASA can provoke bronchospasm, as well as cause attacks of bronchial asthma and other reactions of hypersensitivity. Risk factors are the presence of bronchial asthma in history, hay fever, nasal polyposis, chronic diseases of the respiratory system, as well as allergic reactions to other drugs (eg skin reactions, pruritus, urticaria).

The inhibitory effect of ASA on platelet aggregation persists for several days after admission, which may increase the risk of bleeding during surgery or in the postoperative period. If absolute elimination of bleeding in the course of surgical intervention is absolutely necessary, it is necessary to completely abandon the use of ASA in the preoperative period.

Excess dose of ASA is associated with a risk of gastrointestinal bleeding.

Overdose is especially dangerous in elderly patients.

In severe forms of deficiency of glucose-6-phosphate dehydrogenase, ASA can cause hemolysis and hemolytic anemia. Factors that may increase the risk of hemolysis and hemolytic anemia are fever, acute infections and high doses of the drug.

Influence on the ability to drive a car or perform work that requires an increased speed of physical and mental reactions. Taking AspirinŽ Cardio does not affect the ability to drive a car / moving machinery.

Release Form

Tablets, coated with enteric coating, 100 or 300 mg.

Tablets coated with enteric-coated shell, 100 mg: 10 or 14 tablets. In blisters from Al / PP. 2 bl. On 10 tab. Or 2, 4 or 7 bl. On 14 tab. Placed in a cardboard box.

Tablets coated with enteric-coated shell, 300 mg: 10 or 14 tablets. In blisters from Al / PP. 2 bl. On 10 tab. Or 2 or 4 bl. On 14 tab. Placed in a cardboard box.


Bayer Pharma AG, 51368, Leverkusen, Germany.

RU issued: Bayer Pharma AG, D13342, Berlin, Germany.

107113, Moscow, 3rd Rybinskaya St., 18, p. 2.

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Aspirin Cardio

At a temperature no higher 25 ° C.

Keep out of the reach of children.

The shelf life of the drug Aspirin Cardio

5 years.

Do not use beyond the expiration date printed on the package.

Someone from the Malaysia - just purchased the goods:
Ovagen 60 capsules